Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Aurora Biotechnology Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single pending action is assigned to a single distinct examiner working within 1 distinct art unit. The focused nature of this portfolio suggests a highly specific technical scope or a very early stage of prosecution activity in the United States. Practitioners should note that the current workload is handled by a single individual, which may lead to consistent feedback across the portfolio.
The busiest examiner for this company is FAY, ZOHREH ALEMZADEH, who is responsible for 1 pending office action. This represents the entirety of the company's current pending workload. Because the portfolio involves only 1 distinct examiner and 1 distinct art unit, the prosecution strategy appears concentrated rather than distributed across multiple specialized groups. The alignment of 1 distinct examiner with 1 pending action suggests that the company is not currently facing a high volume of simultaneous challenges from multiple USPTO officials. This concentration allows for a very direct line of communication between the applicant and the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578761 | SACUBITRIL VALSARTAN SODIUM SUSTAINED-RELEASE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | FAY, ZOHREH ALEMZADEH | 62d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578761 | SACUBITRIL VALSARTAN SODIUM SUSTAINED-RELEASE COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Final Rejection | 62d | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Aurora Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zohreh Alemzadeh Fay has the most, with 1 of Shanghai Aurora Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.